Sino Biopharmaceutical Li... (SBMFF)
OTC: SBMFF
· Real-Time Price · USD
0.99
0.00 (0.10%)
At close: Aug 13, 2025, 12:40 PM
0.99
0.00%
After-hours: Aug 13, 2025, 08:00 PM EDT
Sino Biopharmaceutical Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 6.5B | 6.5B | 7.94B | 7.94B | n/a | 7.64B | 7.64B | 4.04B | 6.79B | 7.6B | 7.6B | 6.25B | 6.25B | 7.11B | 7.24B |
Cost of Revenue | 1.25B | 1.25B | 1.42B | 1.42B | n/a | 1.63B | 1.63B | 110.06M | 1.42B | 1.48B | 1.48B | 1.29B | 1.29B | 1.34B | 1.42B |
Gross Profit | 5.25B | 5.25B | 6.51B | 6.51B | n/a | 6.01B | 6.01B | 3.93B | 5.38B | 6.12B | 6.12B | 4.96B | 4.96B | 5.77B | 5.83B |
Operating Income | 1.34B | 1.34B | 1.8B | 1.8B | n/a | 1.56B | 1.56B | 864.76M | 1.36B | 1.58B | 1.58B | 805.68M | 805.68M | 1.78B | 1.24B |
Interest Income | n/a | n/a | n/a | n/a | n/a | 3.08M | 3.08M | 15.51M | 15.51M | 22.35M | 22.35M | 86.21M | 86.21M | 59.31M | 19.55M |
Pretax Income | 831.73M | 831.73M | 1.81B | 1.81B | n/a | 1.61B | 1.61B | 448.26M | 1.01B | 1.88B | 1.88B | 3.8B | 3.8B | 8.14B | 2.84B |
Net Income | 241.34M | 241.34M | 1.51B | 1.51B | n/a | 629.39M | 629.39M | -173.2M | 311.27M | 960.52M | 960.52M | 3.06B | 3.06B | 6.57B | 1.91B |
Selling & General & Admin | 2.66B | 2.66B | 3.42B | 3.42B | n/a | 3.22B | 3.22B | 1.96B | 2.82B | 3.47B | 3.47B | 2.96B | 2.96B | 3.29B | 3.5B |
Research & Development | 1.26B | 1.26B | 1.29B | 1.29B | n/a | 1.18B | 1.18B | 1.05B | 1.14B | 1.02B | 1.02B | 982.74M | 982.74M | 767.05M | 1.01B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.91B | 3.91B | 4.71B | 4.71B | n/a | 4.4B | 4.4B | 3.46B | 4.38B | 4.26B | 4.26B | 1.25B | 1.25B | 2.3B | 3.01B |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 75.56M | 71.66M |
Selling & Marketing Expenses | 2.14B | 2.14B | 2.9B | 2.9B | n/a | 2.69B | 2.69B | 1.75B | 2.3B | 2.88B | 2.88B | 2.43B | 2.43B | 2.61B | 3.05B |
Cost & Expenses | 5.16B | 5.16B | 6.14B | 6.14B | n/a | 6.03B | 6.03B | 3.57B | 5.8B | 5.74B | 5.74B | 2.54B | 2.54B | 3.64B | 4.42B |
Income Tax Expense | 60.59M | 60.59M | 307.05M | 307.05M | n/a | 262.37M | 262.37M | 23.03M | 102.3M | 285.7M | 285.7M | 310.48M | 310.48M | 889.97M | 446.94M |
Shares Outstanding (Basic) | 17.24B | 17.24B | 20.32B | 20.32B | 18.55B | 18.57B | 18.57B | 16.05B | 21.03B | 20.87B | 20.87B | 20.52B | 20.52B | 19.26B | 20.62B |
Shares Outstanding (Diluted) | 18.18B | 18.18B | 18.41B | 18.47B | 18.57B | 18.56B | 18.56B | 18.91B | 18.91B | 19.12B | 19.12B | 19.28B | 19.28B | 19.29B | 19.29B |
EPS (Basic) | 0.01 | 0.01 | 0.07 | 0.07 | n/a | 0.03 | 0.03 | -0.01 | 0.01 | 0.05 | 0.05 | 0.15 | 0.15 | 0.34 | 0.09 |
EPS (Diluted) | 0.01 | 0.01 | 0.08 | 0.08 | n/a | 0.03 | 0.03 | -0.01 | 0.02 | 0.05 | 0.05 | 0.16 | 0.16 | 0.34 | 0.10 |
EBITDA | 1.08B | 1.09B | 1.98B | 1.98B | n/a | 1.81B | 1.81B | 1.11B | 1.61B | 1.77B | 1.77B | 1.02B | 1.02B | 8.21B | 2.91B |
EBIT | 849.53M | 849.53M | 1.73B | 1.73B | n/a | 1.52B | 1.52B | 864.76M | 1.36B | 1.58B | 1.58B | 805.68M | 805.68M | 8.21B | 2.91B |
Depreciation & Amortization | 234.96M | 240.6M | 240.6M | 240.6M | -36.81K | 305.69M | 305.69M | 246.4M | 246.4M | 187.88M | 187.88M | 210.79M | 210.79M | 199.5M | 390.53M |